Adlai Nortye (ANL) Non-Current Receivables (2022 - 2025)
Adlai Nortye (ANL) reported Non-Current Receivables of $195.0 million for Q4 2025, up 9.87% year-over-year from $177.5 million in Q4 2024, and up 9.87% on a QoQ basis from $177.5 million in Q4 2024.
Adlai Nortye (ANL) has 4 years of Non-Current Receivables data on file, last reported at $195.0 million in Q4 2025.
- Quarterly Non-Current Receivables rose 9.87% year-over-year to $195.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $195.0 million (up 9.87% YoY) and the FY2025 annual result came in at $195.0 million, up 9.87% from the prior year.
- Non-Current Receivables rose to $195.0 million in Q4 2025 per ANL's latest filing, from $177.5 million in the prior quarter.
- Across five years, Non-Current Receivables topped out at $195.0 million in Q4 2025 and bottomed at $115.7 million in Q4 2022.
- The 4-year median for Non-Current Receivables is $150.3 million (2023), against an average of $152.8 million.
- The widest annual swing landed in 2023, when Non-Current Receivables increased 6.36%; it then soared 44.2% in 2024.
- Tracing ANL's Non-Current Receivables over 4 years: stood at $115.7 million in 2022, then increased by 6.36% to $123.1 million in 2023, then soared by 44.2% to $177.5 million in 2024, then increased by 9.87% to $195.0 million in 2025.
- Per Business Quant, the three latest ANL Non-Current Receivables figures stand at $195.0 million (Q4 2025), $177.5 million (Q4 2024), and $123.1 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | 195.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 195.03 Mn |
| Dec 31, 2024 | 177.51 Mn |
| Dec 31, 2023 | 123.10 Mn |
| Dec 31, 2022 | 115.74 Mn |